Geron Corporation

NASDAQ•GERN

CEO: Dr. John A. Scarlett M.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 1996-07-31

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Contact Information

919 East Hillsdale Boulevard, Suite 250, Foster City, CA, 94404, United States

650-473-7700

www.geron.com

Market Cap

$919.23M

P/E (TTM)

-11.2

19.9

Dividend Yield

52W High

$2.01

52W Low

$1.04

52W Range

41%

Rank56Top 81.7%

2.5

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.5 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$48.02M+0.00%

4-Quarter Trend

EPS

-$0.05+0.00%

4-Quarter Trend

FCF

-$22.10M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

RYTELO Product Revenue Surge Net product revenue reached $183.6M in 2025, showing 58% growth over 2024 sales figures.

Total Revenue Skyrockets Total revenues hit $183.9M in 2025, a 139% increase compared to the prior year's $77.0M.

Cash Position Strong Ended 2025 with $401.1M in cash, cash equivalents, and marketable securities for operations.

Risk Factors

Commercialization Success Dependent Near-term prospects entirely rely on successful U.S. commercialization of RYTELO for lower-risk MDS.

Workforce Reduction Implemented Strategic restructuring announced in December 2025 resulting in workforce reduction of approximately one-third.

Facing Securities Litigation Company and officers named in multiple securities class action and derivative lawsuits; defense costs are substantial.

Outlook

EU Commercialization Planned Preparing for planned RYTELO commercialization launch in select European Union markets throughout 2026.

IMpactMF Trial Analysis Timing Expect interim overall survival analysis for the IMpactMF Phase 3 trial in the second half of 2026.

Operating Expenses Expected Down Expect SG&A expenses to decrease in 2026 due to headcount reduction savings from restructuring efforts.

Peer Comparison

Revenue (TTM)

ARVN

$262.60M

-0.3%

VALN

$198.55M

+13.5%

GERN

$183.88M

+138.8%

Gross Margin (Latest Quarter)

VIR

672.1%

-54902.1pp

DNA

124.4%

-21.7pp

ABUS

97.9%

-2.1pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
TYRA	$1.76B	-16.4	-41.2%	2.1%
VIR	$1.24B	-2.8	-49.3%	18.6%
SVRA	$1.14B	-10.4	-86.6%	21.2%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

6.6%

Steady Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 5, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data